US Bancorp DE Has $5.11 Million Position in Axon Enterprise, Inc. (NASDAQ:AXON)

US Bancorp DE raised its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 2.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,792 shares of the biotechnology company’s stock after buying an additional 284 shares during the quarter. US Bancorp DE’s holdings in Axon Enterprise were worth $5,112,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Axon Enterprise by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock worth $2,547,878,000 after buying an additional 212,401 shares during the last quarter. Motley Fool Asset Management LLC lifted its holdings in shares of Axon Enterprise by 238.7% during the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock worth $153,981,000 after buying an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. lifted its holdings in shares of Axon Enterprise by 44.0% during the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after buying an additional 114,800 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Axon Enterprise by 13.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock valued at $108,496,000 after purchasing an additional 45,049 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in shares of Axon Enterprise by 1.6% during the second quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock valued at $79,571,000 after purchasing an additional 4,365 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Matthew R. Mcbrady sold 2,000 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the transaction, the chief financial officer now owns 98,825 shares of the company’s stock, valued at approximately $37,449,733.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Matthew R. Mcbrady sold 2,000 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares in the company, valued at $1,783,916.72. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 371,172 shares of company stock valued at $137,000,162 over the last 90 days. 6.10% of the stock is owned by company insiders.

Axon Enterprise Price Performance

Shares of AXON stock opened at $431.57 on Tuesday. The stock’s fifty day moving average is $402.34 and its 200-day moving average is $341.15. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The stock has a market capitalization of $32.61 billion, a PE ratio of 113.87, a PEG ratio of 10.78 and a beta of 0.94. Axon Enterprise, Inc. has a 52 week low of $212.88 and a 52 week high of $455.17.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the prior year, the business earned $0.80 earnings per share. The business’s revenue for the quarter was up 34.5% on a year-over-year basis. Equities research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AXON. Needham & Company LLC boosted their price objective on Axon Enterprise from $400.00 to $525.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Barclays boosted their price objective on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. The Goldman Sachs Group boosted their price objective on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. JMP Securities boosted their price objective on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Finally, Bank of America assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $392.85.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.